Poor
Not Aligned
Patient Risk:
Low
Summary
Only a small subset of claims (e.g., hydroxyzine active ingredient and some CNS-related side effects such as drowsiness and dry mouth) are supported by the provided label excerpts; many other claims (e.g., antihistamine/antiemetic/anticholinergic categorization, generic availability/patent expiry/bioequivalence specifics, nausea/vomiting treatment, and additional less-common adverse reactions) are unsupported or not evidenced in the supplied label text.
Category Scores
Accurate Statements
The active ingredient in Atarax is hydroxyzine hydrochloride.
Supplied label material identifies hydroxyzine/Atarax as hydroxyzine hydrochloride (e.g., contraindications/precautions/adverse reactions sections referencing hydroxyzine and Atarax).
Common side effects of Atarax can include drowsiness.
ADVERSE REACTIONS: 'Central Nervous System: Drowsiness is usually transitory...'
Common side effects of Atarax can include dry mouth.
ADVERSE REACTIONS: 'Anticholinergic: Dry mouth.'
Unsupported Statements
Atarax is an antihistamine with antiemetic and anticholinergic properties.
The provided label excerpts explicitly list 'Anticholinergic: Dry mouth' but do not support the 'antihistamine' and 'antiemetic' claims, nor do they define Atarax as an antihistamine/antiemetic in the supplied text.
Atarax is used to treat anxiety.
The supplied label excerpts include dosage for anxiety-related indications ('symptomatic relief of anxiety and tension...') but the provided evaluation text does not clearly map this to the specific claim set beyond the DOSAGE excerpt; overall, the evidence provided in the prompt is insufficient to treat the claim as fully supported for indication without explicitly quoted INDICATIONS language for anxiety.
Atarax is used to treat itching associated with allergic conditions.
While the DOSAGE excerpt includes pruritus due to allergic conditions (chronic urticaria/atopic/contact dermatoses), the claim is framed as an indication and the provided evidence does not include an explicit INDICATIONS excerpt stating 'itching associated with allergic conditions' as an approved indication.
Atarax can be used to treat nausea and vomiting.
No supplied label excerpts state nausea/vomiting is an indication or supported use.
Atarax is available in generic form.
No supplied prescribing information excerpts address generic availability.
The original patent for Atarax has long expired, allowing for the production of generic versions.
No supplied prescribing information excerpts address patent status.
Generic Atarax is hydroxyzine hydrochloride.
No supplied prescribing information excerpts discuss generic drug composition/identity.
Generic Atarax is widely available at most pharmacies.
No supplied prescribing information excerpts address availability.
Generic Atarax can be prescribed by a healthcare provider.
No supplied prescribing information excerpts address prescribing rules for generics.
Generic medications, including generic Atarax, are bioequivalent to their brand-name counterparts.
No supplied prescribing information excerpts discuss bioequivalence.
Generic Atarax contains the same active ingredient, dosage form, strength, and route of administration as the brand-name Atarax.
No supplied prescribing information excerpts discuss generic equivalence specifications.
Generic Atarax is proven to work in the body in the same way as the brand-name counterpart.
No supplied prescribing information excerpts discuss proof of interchangeability/effects for generics.
Common side effects of Atarax can include blurred vision.
No supplied label excerpt lists blurred vision as an adverse reaction.
Less common side effects of Atarax may involve dizziness.
No supplied label excerpt lists dizziness as an adverse reaction.
Less common side effects of Atarax may include constipation.
No supplied label excerpt lists constipation as an adverse reaction.
Less common side effects of Atarax may include difficulty urinating.
No supplied label excerpt lists difficulty urinating as an adverse reaction.
Contradictions
Important Omissions
No dosage/administration claims were provided in the AI response set for Atarax (e.g., specific mg dosing, q.i.d. schedules, or pediatric dosing) despite DOSAGE being a relevant label section.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Some safety-relevant claims (drowsiness; dry mouth anticholinergic effect; CNS depressant potentiation and driving caution) are consistent with provided label excerpts, but several unsupported claims could mislead about unlisted indications (nausea/vomiting) and unlisted adverse effects (blurred vision, dizziness, constipation, difficulty urinating), which may affect patient counseling fidelity rather than contradicting label safety statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major portions of the claim set are not supported by the provided prescribing information excerpts, including generic/patent/bioequivalence statements and adverse reaction/indication claims not evidenced in the supplied label text (notably nausea/vomiting and several adverse effects).
Suggested Improvement
Restrict claims to label-supported content from the provided excerpts (e.g., active ingredient identity; dry mouth and drowsiness; CNS depressant potentiation and related warnings). Remove generic/patent/bioequivalence and any adverse reaction or indication claims that are not explicitly supported by the supplied label text.